Patients’ Right to Know Their Medication Act of 2025
- Sponsor
- Rep. Bentz, Cliff [R-OR-2]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Sep 4, 2025
Bottom line
This bill seeks to enhance patient safety and reduce healthcare costs by requiring standardized, clear, paper-based patient medication information for all prescription drugs dispensed outside of hospitals.
What it actually does
This bill mandates the Food and Drug Administration (FDA) to issue regulations requiring standardized, patient-friendly, paper-format Patient Medication Information (PMI) for all prescription drugs dispensed in non-hospital settings. The PMI must be scientifically accurate, approved by the Secretary, developed by manufacturers, and provided with each prescription, aiming to improve patient understanding and reduce adverse drug events.
Proponents argue
Proponents argue that standardized paper PMI will significantly reduce adverse drug events, improve patient understanding and adherence, and lead to substantial healthcare cost savings by preventing emergency room visits and hospital admissions. They emphasize the necessity of a paper option for patients lacking electronic access and highlight the current absence of a mandated, patient-friendly format.
Opponents contend
Potential opponents might raise concerns about the increased regulatory and operational burden on pharmaceutical manufacturers and pharmacies for developing, printing, and distributing standardized paper PMI. They could argue this might lead to higher drug costs, delays in drug availability, or that electronic formats are more efficient and environmentally friendly for a significant portion of the population.
The bill is concise and clearly written, allowing for a quick and straightforward understanding of its core purpose and provisions.
Section 3(a), inserting new Section 505H(a) into the FD&C Act
Mandate for FDA to Issue PMI Regulations
This provision requires the Secretary of Health and Human Services (acting through the FDA) to issue final regulations within one year of the bill's enactment. These regulations will govern the authorship, content, format, color, printing, and dissemination requirements for patient medication information (PMI) for all prescription drugs.
Supporters argue
Supporters argue that this mandate is a critical initial step to ensure consistent and effective patient information across the pharmaceutical industry, leveraging the FDA's expertise and authority to establish necessary standards.
Critics contend
Critics might contend that a one-year deadline for such comprehensive regulations is overly ambitious, potentially leading to rushed or incomplete rules that could create unforeseen challenges for both regulators and industry.
Tradeoffs
This provision balances the urgent need for standardized patient safety information with the inherent complexity and time required to develop robust, industry-wide regulations.
Section 3(a), inserting new Section 505H(b) into the FD&C Act
Specific Content and Format Requirements for PMI
This section details the mandatory content and presentation of the patient medication information. It requires PMI to be scientifically accurate, FDA-approved, developed by manufacturers, in plain language with graphics, standardized format (including font and color), printed on paper, non-promotional, and include specific details like drug name, indications, directions, warnings, side effects, patient actions to reduce risks, healthcare professional contact, storage/disposal, drug interactions, subpopulation data, manufacturer contact, and a link for adverse event reporting. It also mandates one printed PMI per prescription.
Section 3(a), inserting new Section 505H(c) into the FD&C Act
Timeliness, Consistency, Accuracy, and Effectiveness Requirements for PMI
This provision mandates that the FDA's regulations must ensure timely reviews and updates of PMI, consistency across similar products to prevent confusion, and that all specifications for language, graphics, and format are based on documented patient research demonstrating improved learning and understanding. Crucially, the regulations must be based on a demonstrated causal connection between enhanced PMI and improved patient medication adherence, compliance, reduced healthcare costs, and improved medical outcomes.
Section 3(b), amending Section 502 of the FD&C Act
Failure to Provide PMI as a Misbranding Offense
This provision amends the Federal Food, Drug, and Cosmetic Act to classify any prescription drug as 'misbranded' if its patient medication information is not provided in accordance with the new Section 505H. Misbranding is a serious regulatory violation that can lead to product seizures, injunctions, and other enforcement actions by the FDA.
This subsection defines 'adequate supply' for patient medication information, specifying that it means enough printed PMI to provide one copy per prescription, even when the drug packaging contains a bulk amount intended for multiple prescriptions.
Section 3(a), inserting new Section 505H(d) into the FD&C Act
Why it matters:This is standard legislative practice for defining terms that are critical for the practical implementation of a broader policy, ensuring clarity in application.
Case for: This definition is crucial for ensuring that every patient receives their own individual PMI, regardless of how the drug is packaged or dispensed (e.g., from a large bottle at a pharmacy). It prevents situations where a single PMI might be expected to serve multiple patients.
Case against: This could be viewed as adding to the printing and packaging burden for manufacturers, especially for drugs typically dispensed from bulk, and potentially leading to increased paper waste if not all bulk-packaged units are ultimately dispensed as individual prescriptions.
Estimated impact: Ensures consistent patient access to critical medication information regardless of dispensing method; results in a minor increase in printing and packaging costs for manufacturers.